The USFDA gives Zydus its final approval for Zinc Sulphate Injection Pharmacy Bulk Package Vials

24 Aug 2023 , 02:51 PM

Zinc Sulphate Injection USP, 10 mg/10 mL (1 mg/mL), 30 mg/10 mL (3 mg/mL), and 25 mg/5 mL (5 mg/mL) Pharmacy Bulk Package Vials (USRLD: Zinc Sulphate Injection USP, 10 mg/10 mL (1 mg/mL), 30 mg/10 mL (3 mg/mL), and 25 mg/5 mL (5 mg/mL) have received final FDA approval.

When oral or enteral feeding is not feasible, insufficient, or inappropriate, zinc sulphate injection is recommended for use in adult and pediatric patients as a source of zinc for parenteral nutrition. The group’s formulation production facility in Jarod is where the medication will be made.

In the United States, sales of pharmacy bulk package vials of zinc sulphate injection USP, 10 mg/10 mL (1 mg/mL), 30 mg/10 mL (3 mg/mL), and 25 mg/5 mL (5 mg/mL) totaled USD 17.1 mn in 2018 (IQVIA MAT June 2023).

The group has submitted over 444* ANDAs since the filing procedure began in FY 2003–2004, and it now has 377 approvals.

Zydus Lifesciences Limited’s shares were last traded on the BSE for Rs. 645.30, down from the previous closing of Rs. 650.95. 

The stock’s intraday high and low were Rs. 656.20 and Rs. 641.85, respectively. 

For feedback and suggestions, write to us at [e-mail]